http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2968483-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfb0281008cb570feea037cd350c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbdae384a9f1ad0588422c89ddc71a00
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6489
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24087
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
filingDate 2014-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3efdda721f553207111127f23b7ae24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b1010243c9ca197c231be332c0743a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af84c820902d55b5f6d598dcbfba7bfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c08694a600f4acfa453477837757a6f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc27e7c5ef0c9d1f98b1b1b5dc423c8e
publicationDate 2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2968483-A1
titleOfInvention Subcutaneous administration of adamts13
abstract This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
priorityDate 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3821
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID35775
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395405
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395404
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405859
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644025
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335613
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226487577
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406322
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54740249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73896894
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226486686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID26533
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23663404
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54684461
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226431830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395791

Total number of triples: 48.